The capital round, led by Vensana Capital and Mutual Capital Partners with participation from Neovate Capital Partners, will fund broader commercial access and new clinical studies. The B3 GEL® System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, and muscles during the critical post-operative window. Unlike traditional sheet-based barriers, the gel conforms to complex anatomy, allowing surgeons to integrate it into existing workflows without added complexity.

Tim Keane, co-founder and CEO of TYBR Health, views the funding as a catalyst for a shift in surgical philosophy. As the company scales, it aims to generate the clinical evidence necessary to prove that managing the biological environment is as vital as the initial repair. Following the investment, Greg Banker of Vensana and Liz Todia Zambory of Mutual Capital Partners will join the company’s Board of Directors to guide this expansion.